containing protein 4 (NLRC4), absent in melanoma 2 (AIM2), and broadly regulates inflammasome activation. PKR autophosphorylation in a cell-free system with recombinant NLRP3, apoptosisassociated speck-like protein containing a CARD (ASC, also known as PYCARD) and pro-caspase-1 reconstitutes inflammasome activity. These results show a crucial role for PKR in inflammasome activation, and indicate that it should be possible to pharmacologically target this molecule to treat inflammation.
HMGB1, a ubiquitous nuclear and cytosolic protein, is released into the extracellular space during sterile inflammation and infection 6 . Immunocompetent cells secrete HMGB1 after stimulation with microbial products and other danger signals [4] [5] [6] . Ischaemic and injured somatic cells also release HMGB1, but in this case the release mechanisms are passive 6 . Extracellular HMGB1 signals through Toll-like receptor 4 (TLR4) receptors in macrophages to induce cytokine release 6, 7 and mediate cell migration by interacting with receptor for advanced glycation end-products (RAGE) 8 . The importance of these mechanisms in disease pathogenesis has been established, because neutralizing HMGB1 attenuates disease severity in infectious and sterile injury syndromes such as arthritis, colitis, sepsis and ischaemia reperfusion 6 . The mediator role of HMGB1 at the intersection of both sterile and infectious inflammation highlights the importance of mechanisms that regulate the secretion of HMGB1 from immune cells 6 .
Early observations suggested that secretion of HMGB1 from macrophages requires inflammasome and caspase activity [3] [4] [5] 9, 10 , and is highly associated with HMGB1 translocation from the nucleus to the cytoplasm 4, 6 . HMGB1 is also a universal sentinel to viral invasion, and its release can be stimulated by polyinosinic:polycytidylic acid (poly(I:C)), a double-stranded RNA (dsRNA) mimetic 11, 12 . Because we were interested in studying HMGB1 release mechanisms from macrophages exposed to poly(I:C), we first considered earlier observations that PKR is phosphorylated in these conditions 13, 14 . As PKR is also activated by prototypical pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) known to stimulate HMGB1 release 15, 16 and activate the inflammasome, we reasoned that PKR activation might participate in inflammasome activation.
Accordingly, we measured HMGB1 release by peritoneal macrophages obtained from PKR-deficient (Pkr 2/2 ) mice, in which the PKR kinase domain had been functionally inactivated by genetic deletion 16 . HMGB1 secretion after poly(I:C) exposure in Pkr 2/2 macrophages was significantly lower than in wild-type (Pkr 1/1 ) macrophages ( Fig. 1a ). Pharmacological inhibition of PKR in Pkr 1/1 macrophages dose-dependently, and significantly, inhibited poly(I:C)-induced HMGB1 release and PKR phosphorylation ( Fig. 1b and Supplementary Fig. 1 ). Other prototypical danger signals, including ATP, monosodium urate (MSU), adjuvant aluminium (ALU) and live E. coli, also significantly increased PKR phosphorylation and HMGB1 release ( Fig. 1c-e ). Addition of potassium to the extracellular space significantly inhibited ATP-induced PKR activation ( Fig. 1c ). Inactivation of macrophage PKR by genetic deletion (Fig. 1d , e) or pharmacological inhibition ( Fig. 1f and Supplementary Fig. 2 ) also significantly inhibited HMGB1 release.
Pyroptosis, a form of programmed, inflammatory cell death, occurs with macrophage inflammasome activation, and we observed that deletion of PKR significantly inhibited lactate dehydrogenase (LDH) release ( Fig. 1g ). Analysis by tandem mass spectrometry of HMGB1 released in response to ATP, MSU or ALU indicated that HMGB1 was highly acetylated in the nuclear location sequence ( Fig. 1h and Supplementary Figs 3-6). By contrast, HMGB1 released from macrophages subjected to freeze/thaw cycles was not acetylated in the nuclear location sequence (Fig. 1h ). Together with evidence that inflammasome activation participates in the nuclear translocation of HMGB1 (ref. 4), these results indicated that HMGB1 hyperacetylation and release, and inflammasome activation, are regulated by PKR.
To address the role of PKR in activating the NLRP3 inflammasome, we measured caspase-1 activation and IL-1b cleavage in peritoneal macrophages from Pkr 1/1 and Pkr 2/2 mice. Caspase-1 activation and IL-1b cleavage were significantly inhibited in Pkr 2/2 macrophages stimulated by exposure to ATP, MSU and ALU ( Fig. 2a ). Similar results were obtained in bone marrow-derived dendritic cells (BMDCs) ( Supplementary Fig. 7 ) and bone marrow-dervied macrophages (BMDMs) ( Supplementary Fig. 8 ). The expression of NLRP3 and pro-IL-1b did not differ significantly in Pkr 2/2 or Pkr 1/1 macrophages ( Fig. 2a and Supplementary Fig. 9 ), but IL-1b secretion by macrophages exposed to live E. coli. was significantly inhibited in Pkr 2/2 macrophages as compared with Pkr 1/1 macrophages ( Fig. 2b ). Tumour necrosis factor (TNF-a) release in the Pkr 1/1 and Pkr 2/2 macrophages was comparable, indicating that the decreased release of IL-1b in the Pkr 2/2 macrophages is not attributable to a global defect in signal transduction ( Supplementary Fig. 10 ).
Transfection of BMDCs with poly(I:C) and E. coli RNA significantly activated caspase-1 and stimulated IL-1b cleavage in Pkr 1/1 but not Pkr 2/2 cells ( Supplementary Fig. 11 ). Similar observations were obtained in Pkr 2/2 and Pkr 1/1 macrophages stimulated by rotenone, which induces mitochondrial reactive oxygen species production and PKR phosphorylation ( Supplementary Figs 12 and 13 ). Pharmacological inhibition of PKR dose-dependently suppressed MSU-induced caspase-1 activation and IL-1b cleavage. The observed half-maximum inhibitory concentrations (IC 50 values) of 2-aminopurine (2-AP) ( Fig. 2c ) and C 13 H 8 N 4 OS ( Supplementary Fig. 14) were 0.5 mM and 0.25 mM, respectively, which agree closely with their known IC 50 against PKR. PKR inhibition significantly reduced ATP-and ALU-induced inflammasome activation in mouse macrophages ( Supplementary  Figs 15 and 16 ), and in human monocytic THP-1 cells (Supplementary Fig. 17 ). IL-18 release was significantly lower in Pkr 2/2 macrophages than in Pkr 1/1 macrophages stimulated with ATP, MSU or ALU, whereas TNF-a and IL-6 were not suppressed ( Supplementary  Fig. 18 ). The addition of 2-AP reduced MSU-induced IL-18 release, but not TNF-a and IL-6 ( Supplementary Fig. 18 ). 2-AP failed to inhibit MSU-induced caspase-1 activation and IL-1b cleavage in Pkr 2/2 macrophages ( Supplementary Fig. 19 ). Collectively, these findings establish a crucial role for PKR in activating the NLRP3 inflammasome.
Pkr 1/1 and Pkr 2/2 mice were then exposed to live E. coli, to activate the NLRP3 inflammasome in vivo 17 . Serum levels of IL-1b, IL-18 and HMGB1 were significantly reduced in Pkr 2/2 mice as compared with Pkr 1/1 mice ( Fig. 2d ). In agreement with previous evidence suggesting that peritoneal neutrophil infiltration requires inflammasome activation 18 , we observed significantly fewer neutrophils in peritoneal lavage from Pkr 2/2 mice than in Pkr 1/1 controls ( Fig. 2e ). Serum IL-6, an inflammasome-independent cytokine, was comparable in both groups (Fig. 2d ). Exposure of Pkr 2/2 mice to endotoxemia produced significantly lower serum IL-1b and IL-18 levels, but quantitatively similar serum levels of TNF-a and IL-6 as compared with Pkr 1/1 controls ( Supplementary Fig. 20 ). Thus, PKR regulates inflammasome-dependent cytokine release in vivo.
To study the mechanisms of PKR regulation, HEK293A cells, which do not normally express the NLRP3 components, were transfected with plasmids that co-express ASC, pro-caspase-1 and NLRP3. These modified cells were then co-transfected with plasmids that express PKR, or specific short hairpin RNA (shRNA) to suppress endogenous PKR. Overexpression of PKR significantly enhanced caspase-1 activation and IL-1b cleavage, and knockdown of endogenous PKR by shRNA abolished caspase-1 cleavage in the NLRP3 inflammasome-reconstituted cells (Fig. 2f, g) . IL-1b cleavage was significantly abrogated by pharmacological inhibition of PKR (Supplementary Fig. 21 ). PKR overexpression failed to activate caspase-1 directly in the absence of NLRP3 ( Supplementary Fig. 22 ), and did not enhance HMGB1 release in the absence of caspase-1 ( Supplementary  Fig. 23 ). Knockdown of endogenous eIF2a, a PKR substrate 13, 14 , did not 
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alter HMGB1 release and IL-1b cleavage in the NLRP3 inflammasomereconstituted cells ( Supplementary Fig. 24 ). We therefore reasoned that PKR physically interacts with the NLRP3 inflammasome, and prepared mouse macrophage lysates for immunoprecipitation using anti-PKR antibodies. PKR pulled down NLRP3, and reciprocal immunoprecipitation of NLRP3 pulled down PKR ( Supplementary Fig. 25 ). Similar observations were obtained in human THP-1 cells ( Supplementary Fig. 26 ). PKR-NLRP3 complexes could not be detected in the Pkr 2/2 macrophages ( Supplementary  Fig. 27 ). Co-expression of PKR and NLRP3 in HEK293A cells, followed by immunoprecipitation, confirmed the physical interaction between PKR and NLRP3. PKR failed to associate physically with the other cytosolic receptors or inflammasome family members NOD1, NLRP12 or NLRX1 ( Supplementary Fig. 28 ). PKR co-immunoprecipitated with truncated forms of NLRP3 containing the pyrin domain (PYD), NACHT domain and leucine-rich repeat (LRR) domain (Supplementary Fig. 29) , and with the Walker A mutant form of NLRP3 ( Supplementary Fig. 30 ), which cannot bind ATP 19 . Together with direct evidence that recombinant PKR forms a heteromeric protein complex with NLRP3 ( Fig. 3a) , these results indicate that PKR physically interacts with the inflammasome.
Exposure of Pkr 1/1 macrophages to ATP significantly enhanced the formation of NLRP3 and PKR complexes (Fig. 3b ). Pharmacological inhibition of PKR phosphorylation by 2-AP and C 13 H 8 N 4 OS significantly suppressed the formation of NLRP3-PKR complexes (Fig. 3b ). The addition of poly(I:C) and ATP to NLRP3 and PKR in a cell-free system significantly induced PKR phosphorylation and increased the formation of NLRP3-PKR complexes (Fig. 3a) .
Next, the NLRP3 inflammasome was reconstituted in a cellfree system with recombinant NLRP3, ASC, pro-caspase-1 and PKR.
Combining NLRP3 and ASC with pro-caspase-1 failed to increase caspase-1 activity (Fig. 3c ). The addition of PKR and poly(I:C) or ATP significantly increased caspase-1 activity, which was inhibited by the addition of 2-AP ( Fig. 3c ). PKR activity is required in this cell-free system, because poly(I:C)/ATP failed to increase NLRP3 inflammasome activity in the absence of PKR. Moreover, replacing PKR with a recombinant, mutant PKR carrying the Lys296Arg mutation and thus devoid of kinase activity 13, 16 failed to activate the NLRP3 inflammasome ( Fig. 3c ). Although PKR is an autophosphorylating kinase, it was theoretically possible that PKR might phosphorylate inflammasome components directly. Phosphorylation of NLRP3, ASC and caspase-1 could not be detected, although poly(I:C)/ATP significantly stimulated autophosphorylation of PKR (data not shown). To confirm that PKR autophosphorylation is involved in NLRP3 inflammasome activation, the PKR(K296R) mutant and NLRP3 inflammasome components were co-expressed in HEK293A cells. The PKR(K296R) mutant failed to bind NLRP3, whereas wildtype PKR did bind NLRP3 ( Supplementary Fig. 31 ). Overexpression of the PKR(K296R) mutant failed to activate the reconstituted NLRP3 inflammasome in HEK293A cells ( Supplementary Fig. 31 ). Together, these data indicate that PKR physically interacts with NLRP3 and is crucial for inflammasome activation.
Reasoning that PKR might associate with the inflammasome components during assembly, ATP-stimulated macrophage lysates were subjected to gel filtration chromatography. We observed that PKR and NLRP3 eluted together with ASC and caspase-1 in the high molecular mass fraction of the ATP-stimulated macrophage extract ( Fig. 3d and Supplementary Fig. 32 ). Inhibition of PKR activation by 2-AP reduced PKR in the high molecular mass inflammasome fraction ( Fig. 3d and Supplementary Fig. 33 ). Expression of the PKR(K296R) mutant RESEARCH LETTER significantly reduced NLRP3 in the high molecular mass inflammasome fraction, without significantly changing total NLRP3 expression ( Supplementary Fig. 34 ). Rendering cells deficient in PKR also significantly impaired the formation of high molecular mass protein NLRP3 inflammasome complexes, without altering total NLRP3 protein expression levels ( Supplementary Fig. 35 ). Activation of macrophages by exposure to ATP, MSU, ALU or E. coli significantly shifted caspase-1 from the low molecular mass, monomeric fraction, to the high molecular mass protein complexes in Pkr 1/1 macrophages, but not in Pkr 2/2 macrophages ( Supplementary Fig. 35 ). Thus, activated PKR is an integral component of the assembled inflammasome.
Unexpectedly, PKR also physically interacted with NLRP1, AIM2 and NLRC4 when co-expressed in HEK293A cells (Fig. 4a ). To address whether PKR might also regulate NLRP1, AIM2 and NLRC4 inflammasomes, macrophages were stimulated with anthrax lethal toxin, transfected with poly(dA-dT)Npoly(dA-dT) (hereafter termed poly(dA:dT)) or infected with S. typhimurium to activate the NLRP1, AIM2 or NLRC4 inflammasomes, respectively. This significantly enhanced PKR autophosphorylation ( Supplementary Fig. 36 ). Inactivation of PKR by genetic deletion (Fig. 4b-d and Supplementary Figs 37 and 38) or by pharmacological inhibition (Fig. 4e and Supplementary Fig. 39 ) significantly inhibited caspase-1 activation, IL-1b cleavage and HMGB1 secretion. LDH release and IL-18 production were also significantly decreased in Pkr 2/2 macrophages compared with Pkr 1/1 macrophages, whereas TNF-a production was not suppressed in these conditions ( Supplementary Figs 40 and 41) . Overexpression of PKR significantly enhanced NLRP1, AIM2 and NLRC4 inflammasome-induced caspase-1 activation and IL-1b cleavage in HEK293A cells ( Fig. 4f and Supplementary Fig. 42 ). 
Thus, PKR regulates the activation of the NLRP3, NLRP1, AIM2 and NLRC4 inflammasomes, but its activity does not determine which inflammasome will be activated in response to a specific stimulus. Previous observations suggested that macrophage death by pyroptosis might initiate deleterious inflammatory responses and compromise immunity during bacterial infection 5, 15 , and that PKR can participate in bacteria-induced macrophage death 15 . To assess whether PKR deficiency impairs bacterial clearance, Pkr 1/1 and Pkr 2/2 mice were exposed to live E. coli (bearing a genetic marker) into the peritoneal cavity. Titres of the genetically labelled bacteria in the spleen and peritoneal cavity 24 h later were significantly lower in Pkr 2/2 mice than in Pkr 1/1 controls ( Supplementary Fig. 43 ), indicating that the animals maintain the capacity to clear bacteria despite PKR deficiency.
This study establishes that PKR activity is integral to inflammasome assembly and activation. PKR physically interacts with inflammasome components, is important for caspase-1 activation, IL-1b cleavage and HMGB1 release, and mediates inflammasome activity in a cell-free system. Although originally studied as an intracellular sensor of viral dsRNA, a broader role of PKR was recently suggested as a dangersensing molecule activated by cellular and metabolic stress 15, 16, 20 . Together with the established role of the inflammasome and HMGB1 in sterile and infection-associated inflammation 3,6,21-23 , the identification here of PKR as a crucial regulator of inflammasome activity adds to our understanding of the mechanisms of innate immune responses to environmental, metabolic and invasive signals.
Rapidly growing evidence links the inflammasome to the pathogenesis of disease syndromes such as obesity, type 2 diabetes, atherosclerosis, gout, sepsis and colitis 4, 5, 10, 18, 24, 25 . The development of therapeutics targeting the inflammasome requires knowledge of specific upstream signalling pathways that regulate inflammasome assembly and activation 25, 26 . It should now be possible to design and develop therapeutics to inhibit inflammasome activity by specifically targeting PKR, without broadly impairing immunity, in the treatment of non-resolving inflammatory and meta-inflammatory syndromes.
METHODS SUMMARY
Cell stimulation. Peritoneal macrophages, BMDMs or BMDCs from Pkr 2/2 and wild-type Pkr 1/1 mice were primed with ultra-pure LPS (500 ng ml 21 ), and then stimulated with inflammasome agonists. PKR inhibitors were added before exposure to inflammasome stimuli, where applicable. HMGB1 release, caspase-1 activation and IL-1b maturation were assessed by western blot. Reconstituted inflammasome in HEK293A cells. Cells were transfected with plasmids expressing pro-IL-1b and inflammasome components, such as ASC, pro-caspase-1, NLRP3 and NLRP1. These modified cells were then co-transfected with plasmids that express PKR, or specific shRNA to knockdown the endogenous PKR. After 24 h, cell lysates were collected and analysed for IL-1b maturation and caspase-1 activation by western blot. Reconstituted inflammasome in a cell-free system. Recombinant NLRP3, ASC and pro-caspase-1 were incubated with recombinant PKR and with ATP (2.5 mM) or poly(I:C) (1 ng ml 21 ) in the PKR reaction buffer at 37 uC for 1 h. Caspase-1 activity was measured by hydrolysis of the synthetic peptide WEHD-pNA. E. coli-induced peritonitis. Pkr 2/2 and Pkr 1/1 mice were injected intraperitoneally with live E. coli (2 3 10 9 per mouse). After 6 h, blood was collected and the serum levels of IL-1b, IL-18, HMGB1 and IL-6 were measured by ELISA assay.
Full Methods and any associated references are available in the online version of the paper.
